In this study, we assessed a cohort of cutaneous melanoma patients with ARID mutations to identify the ARID2 mutation’s impact on prognosis and response to ICI treatment for cutaneous melanoma patients. The gene discussed is ARID2; the disease is cutaneous melanoma.